Comment on

• Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.

  Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. Vescio R, et al. Blood. 1999 Mar 15;93(6):1858-68. Blood. 1999. PMID: 10068658 Clinical Trial.
• Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.

  Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. Holmberg LA, et al. Blood. 1999 Dec 15;94(12):4029-35. Blood. 1999. PMID: 10590046 Clinical Trial.